Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Peter Thompson
AddedMar 31, 2024
UpdatedMay 31, 2026
Peter Thompson

Peter Thompson

Board Member, Alpine Immune Sciences

Crunchbase

Peter Thompson's Career

Alpine Immune Sciences
Alpine Immune Sciences

Seattle, WA, US

Board Member· Board
ARS Pharmaceuticals
ARS Pharmaceuticals

San Diego, CA, US

Board Member· Board
Janux Therapeutics
Janux Therapeutics

San Diego, CA, US

Board Member· Board
Escape Bio
Escape Bio

South San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Peter Thompson's Career

Alpine Immune Sciences
Alpine Immune Sciences
Acquired$475.3M02015Seattle, WA, US
Board Member· Board

Leadership at Alpine Immune Sciences

Mitchell H. GoldMitchell H. GoldBoard Member
Ryan SwansonRyan SwansonCo-Founder
Jörn DrappaJörn DrappaBoard Member
Michael KornackerMichael KornackerCo-Founder
Mitchell GoldMitchell GoldCo-Founder & CEO

Similar to Alpine Immune Sciences

InimmuneInimmuneMissoula, MT, USImmunotherapeuticsest. 2016InimmuneMissoula, MT, US · est. 2016

Inimmue: A cutting-edge biotech firm, pioneering next-gen immunotherapeutics.

Series A · $22.6M15
ImmunomeImmunomeExton, PA, USCancer Therapiesest. 2008ImmunomeExton, PA, US · est. 2008

Immunome, a Philadelphia-based biotech company, develops innovative cancer immunotherapies.

Public · $218.9M48
ImmuneIDImmuneIDBoston, MA, USImmunology Therapeuticsest. 2020ImmuneIDBoston, MA, US · est. 2020

ImmuneID: A precision immunology firm targeting antibody interactions to combat immune diseases.

Series A · $67M48
EquilliumEquilliumLos Angeles, CA, USBiotechnologyest. 2017EquilliumLos Angeles, CA, US · est. 2017

Equillium, Inc.: A clinical-stage biotech firm in California, innovating solutions for autoimmune and inflammatory disorders.

Public · $85M45
ARS Pharmaceuticals
ARS Pharmaceuticals
Public$75M532015San Diego, CA, US
Board Member· Board

Leadership at ARS Pharmaceuticals

Pratik ShahPratik ShahBoard Member
Richard LowenthalRichard LowenthalCo-Founder & CEO
Laura ShawverLaura ShawverBoard Member
Michael KellyMichael KellyBoard Member
Saqib IslamSaqib IslamBoard Member
Sarina TanimotoSarina TanimotoCo-Founder

Similar to ARS Pharmaceuticals

Bryn PharmaBryn PharmaBeverly Hills, CA, USPharmaceuticalsest. 2017Bryn PharmaBeverly Hills, CA, US · est. 2017

Bryn Pharma: Providing easy-to-use, portable nasal epinephrine for anaphylaxis treatment.

Series B · $125.2M5
Amphastar PharmaceuticalsAmphastar PharmaceuticalsRancho Cucamonga, CA, USBiologics, Pharmaceuticalsest. 1996Amphastar PharmaceuticalsRancho Cucamonga, CA, US · est. 1996

Amphastar Pharmaceuticals: A leading US-based specialty pharma company, expert in developing injectable and inhalation products.

Public · $300M1.6k
AktivaxAktivaxAurora, CO, USDrug Deliveryest. 2008AktivaxAurora, CO, US · est. 2008

Aktivax innovates drug delivery tech for emergencies, offering robust auto-injectors with extended shelf life.

Angel · $515.3k7
AdrenaCardAdrenaCardMinneapolis, MN, USMedical Devicesest. 2014AdrenaCardMinneapolis, MN, US · est. 2014

AdrenaCard: Integrating life-saving drugs with user-friendly devices for easy carry.

Angel · $1M5
Janux Therapeutics
Janux Therapeutics
Public$252.4M702017San Diego, CA, US
Board Member· Board

Leadership at Janux Therapeutics

Alana McNultyAlana McNultyBoard Member
Vickie CappsVickie CappsBoard Member
Sheila GujrathiSheila GujrathiBoard Member
David CampbellDavid CampbellFounder
Dave Campbell [LION] 13,000Dave Campbell [LION] 13,000CEO
Escape Bio
Escape Bio
Series D$187.1M392015South San Francisco, CA, US
Board Member· Board

Leadership at Escape Bio

Peter MoldtPeter MoldtBoard Member
Edward OwensEdward OwensBoard Member
Julie Anne SmithJulie Anne SmithBoard Member
Yadong HuangYadong HuangFounder

Similar to Escape Bio

Denali TherapeuticsDenali TherapeuticsSan Francisco, CA, USBiotechest. 2015Denali TherapeuticsSan Francisco, CA, US · est. 2015

Denali Therapeutics, a US-based biotech firm, develops medicines for neurodegenerative diseases.

Public · $622M427
CuraSen TherapeuticsCuraSen TherapeuticsSan Carlos, CA, USDrugsest. 2016CuraSen TherapeuticsSan Carlos, CA, US · est. 2016

CuraSen: A biotech firm innovating drugs for CNS and neurodegenerative diseases enhancement.

Series A · $95.9M38
ConvalesceConvalesceSan Francisco, CA, USStem Cell Therapyest. 2018ConvalesceSan Francisco, CA, US · est. 2018

Convalesce: Pioneering stem cell therapies for neurodegenerative conditions using advanced biomaterials.

Angel · $250k3
Engrail TherapeuticsEngrail TherapeuticsSan Diego, CA, USPharmaceuticalsest. 2019Engrail TherapeuticsSan Diego, CA, US · est. 2019

Developing and commercializing transformative medicines for life-limiting nervous system diseases.

Series A · $64M23

Peter Thompson's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Peter Thompson

Gregor CosterGregor CosterBoard Member · Accident CompensationPeter JenkinsPeter JenkinsCo-Founder · QuVa PharmaPeter ClarkPeter ClarkBoard Member · Atrium HealthThad DruffelThad DruffelBoard Member · Bert Thin FilmsPeter CavanaghPeter CavanaghFounder · JointMetrix MedicalRoberto De PontiRoberto De PontiBoard Member · OncoResponse